DUBLIN, Ireland, Oct. 16, 2025 (GLOBE NEWSWIRE) — Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel” or the “Company”), a leading provider of full-service energy engineering, advisory, and utility solutions, today announced that it has signed a Subscription and Shareholders Agreement (the “Joint Venture Agreement”) with Alien Fuel (Proprietary) Limited (“Alien Fuel”) to formally establish their joint venture vehicle, Biosteam Energy Proprietary Ltd (“Biosteam Energy”), for the Fairfield Industrial Decarbonization Project (the “Fairfield Project”) in Howick, KwaZulu-Natal, South Africa. Under the joint venture structure, Fusion Fuel will hold a 51% ownership stake in Biosteam Energy, with Alien Fuel retaining 49%. Under the terms of the Fairfield Project and the Joint Venture Agreement, Biosteam Energy will manage the financing,...

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function  Demonstrated superior inhibition of pDCs vs. litifilimab in vitro and superior Ig reductions vs. povetacicept in NHPs highlight the potential for improved clinical benefit in severe autoimmune diseases DNTH212 has the potential to be a first line biologic in multiple autoimmune disorders with patient-friendly S.C. self-administration and Q4W or less frequent dosing IND cleared by FDA in September 2025 and expected to clear in China in Q4’25. Phase 1 study of DNTH212 expected to initiate in Q4’25 with top-line results in healthy volunteers in 2H’26 Pro forma estimated cash of ~$525 million; reaffirms runway into 2028 Investor conference...

CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 30, 2025, at 8:00 a.m. ET to report its third quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event. About Agios: Fueled by Connections to Transform Rare Diseases™At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build...

Now through Dec. 31, donations to Beelieve will be matched to fund Bee participation for schools in under-resourced communitiesBeelieveScripps National Spelling Bee, Scripps Howard Fund launch campaign to empower next generation of spellersCINCINNATI, Oct. 16, 2025 (GLOBE NEWSWIRE) — The Scripps Howard Fund and the Scripps National Spelling Bee have launched “Beelieve,” a new campaign to expand access to the Bee for students from schools in under‑resourced communities. In celebration of the Bee’s 100th anniversary this year, the first $100,000 in donations will be matched by the Adam R. Scripps Foundation. Beelieve will provide free enrollment and program resources to partner Title 1 schools during the 2025-26 school year so even more students can benefit from the Bee’s yearlong program. “Every student deserves the chance...

TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it will be presenting at the Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClub on Wednesday, October 22, 2025 at 9:30 AM (EST) at the Arcadian Loft in Downtown Toronto. Tom Looby, Chief Executive Officer of Conavi Medical, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClubDate: Wednesday, October 22, 2025Time: 9:30 AM (Toronto, ON Local...

HYPHEN features brand new best-in-class technology that allows consumers to flex between extracts, size formats and brands through interchangeable vape pods CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the launch of HYPHEN, driving further momentum for the Company’s expanding vape portfolio with the exclusive rollout of HYPHEN’s all-in-one pod system. With a modular battery design that utilizes pod-functionality to serve multiple oil and volume categories within the same base unit, HYPHEN offers consumers the freedom and flexibility to use a variety of oils, sizes and formats without the hassle of juggling between different devices. Beginning October 18, HYPHEN will hit dispensary shelves across...

BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it will participate in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. Gene Mack, President and CEO of Gain, will be participating in a live discussion, “Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutics Categories”, on October 22nd. The panel will include discussion about innovative approaches for a range of neurogenerative diseases that are in active clinical trials, If you are interested in meeting with Gain management, please contact your Maxim sales...